Clinical Trial

Risk-adapted Therapy in HPV-positive Oropharyngeal Cancer Using Circulating Tumor (ct) HPV DNA Profiling (ReACT 2.0)

Not Yet Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The purpose of this study is to assess risk for HPV driven oropharyngeal cancers by using HPV blood tests and clinical features (such as tumor stage and smoking status) to determine appropriate treatment to improve survival outcomes in participants with stage I, II, or III, HPV-associated oropharyngeal (tongue base or tonsil) squamous cell carcinoma,.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2026-04-06.
Trial Details
NCT Number NCT07513324
Lead Sponsor Dana-Farber Cancer Institute
Collaborators: Merck Sharp & Dohme LLC
Conditions HPV-positive Oropharyngeal Squamous Cell Carcinoma, Oropharyngeal Squamous Cell Carcinoma
Enrollment 116 participants
Start Date 2026-07-01
Primary Completion 2028-01-01 (estimated)
Study Completion 2030-01-01 (estimated)
Updated on ClinicalTrials.gov 2026-06-09